Analyst Brandon Vazquez Reaffirms Buy on Medtronic, Citing Strong FY2027 Outlook and Attractive Risk‑Reward Profile

William Blair analyst Brandon Vazquez has maintained their bullish stance on MDT stock, giving a Buy rating today.

Brandon Vazquez has given his Buy rating due to a combination of factors that reflect Medtronic’s long‑term value proposition and earnings outlook. He views the company’s updated fiscal 2027 model and recent quarterly performance as supportive of continued growth, with fundamentals that justify upside from current share levels.

He also appears to factor in Medtronic’s diversified portfolio and resilient cash flow, which provide stability through market cycles while funding innovation and shareholder returns. In his assessment, these attributes, combined with the revised projections, make the risk‑reward profile attractive enough to support a Buy recommendation on MDT.

In another report released today, Citi also maintained a Buy rating on the stock with a $110.00 price target.